Rareview Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-4,154
Closed -$410K – 54
2024
Q4
$410K Sell
4,154
-426
-9% -$41.3K 0.3% 48
2024
Q3
$453K Hold
4,580
– – 0.34% 46
2024
Q2
$425K Buy
4,580
+381
+9% +$34.2K 0.41% 41
2024
Q1
$398K Buy
+4,199
New +$390K 0.39% 41

Other funds holding XBI

Rareview Capital's XBI Position: Q1 2025 in Review

Rareview Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 4,154 shares — an estimated $410K sold.

Rareview Capital first reported a position in XBI in Q1 2024 and held it in 4 quarters. The position peaked at $453K in Q3 2024. 685 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • Rareview Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • Rareview Capital sold 4,154 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $410K.
  • Rareview Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 4 quarters.
  • Rareview Capital's State Street SPDR S&P Biotech ETF position peaked at $453K in Q3 2024.
  • 685 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Rareview Capital's 13F filing for Q1 2025, filed 7 May 2025.